Literature DB >> 15191035

Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity.

Antonio Ponticiello1, Francesco Perna, Sabato Maione, Marino Stradolini, Gianfranco Testa, Giuseppe Terrazzano, Giuseppina Ruggiero, Mario Malerba, Alessandro Sanduzzi.   

Abstract

Cell-mediated immune response can control tuberculosis infection. A significant role for immune cells like CD4, CD8 and gammadelta T lymphocytes have been recognized, but little is known about the kinetics of activation and accumulation of these cells in course of Tuberculosis infection in humans. This is due to both the difficult to access to human lung and the fact that most subjects are examined in different periods of infection which may condition T cell changes. To overcome these problems, we have used intravesical BCG (Bacillus Calmette-Guerin) treatment for preventing the recurrences of bladder cancer as an in vivo experimental model of human tuberculosis infection. 20 male caucasian patients with proven bladder superficial transitional cell carcinoma treated with transurethral resection followed by six weekly intravesical instillations of BCG (T0-T6) were enrolled. Changes in T lymphocyte subsets were assessed by flow cytometry in the bladder wash recovered after each BCG instillation. Our study shows that the action of BCG appears to be T cell dependent. Lymphocytes increase at any new instillation and tend towards the reduction with the suspension of the stimulus. BCG induces a massive increase in the proportion of CD4 Th1 subset followed by an increase in gammadelta T cells, while no significant variation for CD8 and NK cells is found. Our results suggest that BCG infection model represents a valid experimental tool to study the immunological events evoked in vivo by Mycobacterium tuberculosis in humans at the site of infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191035     DOI: 10.1016/j.rmed.2003.12.003

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  13 in total

1.  CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.

Authors:  Padmanee Sharma; Yu Shen; Sijin Wen; Sachiko Yamada; Achim A Jungbluth; Sacha Gnjatic; Dean F Bajorin; Victor E Reuter; Harry Herr; Lloyd J Old; Eiichi Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

2.  Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.

Authors:  Rafael Nunez-Nateras; Erik P Castle; Cheryl A Protheroe; Melissa L Stanton; Tolgay I Ocal; Erin N Ferrigni; Sergei I Ochkur; Elizabeth A Jacobsen; Yue-Xian Hou; Paul E Andrews; Thomas V Colby; Nancy A Lee; James J Lee
Journal:  Urol Oncol       Date:  2013-09-18       Impact factor: 3.498

Review 3.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

Review 4.  Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.

Authors:  Timothy P Kresowik; Thomas S Griffith
Journal:  Immunotherapy       Date:  2009-03       Impact factor: 4.196

5.  The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytes.

Authors:  Kristian Krpina; Emina Babarović; Gordana Dorđević; Zeljko Fuckar; Nives Jonjić
Journal:  Croat Med J       Date:  2012-12       Impact factor: 1.351

6.  T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept.

Authors:  Alexandre Ingels; Rafael E Sanchez Salas; Vincent Ravery; Gaëlle Fromont-Hankard; Pierre Validire; Jean-Jacques Patard; Géraldine Pignot; Dominique Prapotnich; Fabien Olivier; Marc Galiano; Eric Barret; Francois Rozet; Nina Weber; Xavier Cathelineau
Journal:  Ecancermedicalscience       Date:  2014-12-01

7.  Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis.

Authors:  Julia Elsäßer; Martin W Janssen; Frank Becker; Henrik Suttmann; Kai Schmitt; Urban Sester; Michael Stöckle; Martina Sester
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

8.  Different subsets of macrophages in patients with new onset tuberculous pleural effusion.

Authors:  Ying Tang; Shu-Cheng Hua; Gui-Xiang Qin; Li-Jun Xu; Yan-Fang Jiang
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

9.  Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.

Authors:  Renate Pichler; Josef Fritz; Claudia Zavadil; Georg Schäfer; Zoran Culig; Andrea Brunner
Journal:  Oncotarget       Date:  2016-06-28

Review 10.  The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.

Authors:  Natalie E Nieuwenhuizen; Prasad S Kulkarni; Umesh Shaligram; Mark F Cotton; Cyrill A Rentsch; Bernd Eisele; Leander Grode; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.